Gene transduction using recombinant adenovirus vector (Ad) is a powerful technology for human gene therapy because these vectors are highly efficient and can transduce a wide variety of cell types and tissues regardless of the mitotic status of the cell. 1, 2 However, several tumors, including melanoma, which is an important target for gene therapy, require high Ad dosage for sufficient gene expression. This requirement arises because of the low or non-existent expression of coxsackie-adenovirus receptor (CAR), the primary Ad receptor on the cell surface. 3 Recently, we reported that compared with conventional Ad, the fiber-mutant Ad containing the RGD peptide in the HI loop of the fiber knob could more efficiently transduce foreign genes into melanoma cells, 4 ,5 glioma cells, 6 and dendritic cells 7, 8 that expressed little or no CAR on their surface. We also demonstrated that intratumoral injection of RGD fibermutant Ad (AdRGD) carrying the human tumor necrosis factor-a (TNFa) cDNA under the control of the cytomegalovirus promoter (AdRGD-TNFa) could improve anti-tumor efficacy at r10 9 vector particles (VP) compared with application of conventional Ad (Ad-TNFa) under the same experimental conditions in an established murine B16 BL6 melanoma model. 5 Although mice injected intratumorally with AdRGD-TNFa or AdTNFa at 10 10 VP exhibited remarkable tumor regression due to hemolytic necrosis, toxic side effects, such as extreme reduction in body weight and sudden death, were also induced by Ad treatment. 4, 5 Therefore, in the present report, we attempted to elucidate the causes of these adverse effects in order to further optimize TNFagene therapy using AdRGD for the treatment of malignant melanomas.
Toloza et al reported that Ad leaked from injected sites into systemic circulation even when small volumes of Ad were carefully delivered. 9 Therefore, the expression of TNFa was expected in various tissues due to infection by Ad disseminated from the tumors. The body weight reduction and sudden death we observed previously in response to intratumoral injection of Ad-TNFa or AdRGD-TNFa at 10 10 VP potentially resulted from TNFa, which is a proinflammatory cytokine that induces critical side effects when administered systemically at high doses. [10] [11] [12] Furthermore, an inflammatory reaction is known to occur in highly Ad-infected organs due to an immune response to Ad. [13] [14] [15] In response to these data, we first investigated the mRNA level of Ad receptors in murine major organs by reverse transcription-polymerase chain reaction (RT-PCR) analysis 5 and the rate of Ad leakage from established B16 BL6 tumors that had been injected with AdRGD or conventional Ad carrying the luciferase reporter gene (AdRGD-Luc and Ad-Luc, respectively). As shown in Figure 1 , six major organs (brain, lung, heart, liver, spleen, and kidney) of C57BL/6 mice exhibited CAR and a v -, b 3 -, and b 5 -integrin mRNA expression. Based on the Ad-infection mechanism, [16] [17] [18] these results suggested that Ad or AdRGD that are present in systemic circulation could infect and transduce nearly all organs. In fact, luciferase activity was detected in all examined organs on day 2 after intravenous injection of Ad-Luc or AdRGD-Luc in an Ad-dose-dependent manner (Figure 2a ). In addition, luciferase activity at 10 8 or 10 9 VP was higher in the AdRGD-Luc-injected group than in the Ad-Luc-injected group in all organs except the heart. Although the cause of the inverse gene expression patterns in the heart is unknown, these data confirmed the superiority of Ad-RGD over conventional Ad in gene transduction efficiency and expression efficacy in most CAR-expressing organs.
In contrast, luciferase activity in all organs from mice injected with AdRGD-Luc at 10 10 VP was lower than or equivalent to that in Ad-Luc-injected mice. This result agreed with a previous report by Mizuguchi et al that the luciferase activities in heart, lung, liver, kidney, and spleen from mice intravenously injected with a high dose (3 Â 10 10 VP) of Ad-Luc were higher than those in AdRGD-Luc-injected mice on day 2 post Ad-injection. 19 They also discussed that systemically administrated AdRGD might more easily access and attach to mouse erythrocytes in vivo due to its hemagglutination activity, and thus the total vector amounts delivered to each organ can be decreased. Although further studies of the relationship between AdRGD dosage and the level of hemagglutination activity are required, we speculated that the influence of hemagglutination activity of AdRGD on tissue distribution after systemic administration would appear at high dose (above 10 10 VP). More than 99% of total luciferase activity in the six organs was detected in the liver. However, no correlation was observed between the luciferase activity and Adreceptor mRNA levels ( Figure 1 ) in any organ. Since Ad distribution after systemic application would be greatly affected by organ size and conditions in each organ, including the amount of blood flow, blood vessel structure, and presence of a reticuloendothelial system, gene expression efficiency does not rely solely on the expression of Ad receptors. 20, 21 Moreover, it is well known that the liver not only develops a reticuloendothelial system that includes Kupffer cells, 21 but it Total RNA was prepared from six whole organs using Sepasol-RNA I Super (Nacalai Tesque, Kyoto, Japan) according to the manufacturer's instructions. RT-PCR was performed as described previously. 5 In brief, RT proceeded for 60 min at 421C in a 100 ml reaction mixture containing 10 mg total RNA treated with DNase I. PCR amplification (30 cycles) of the CAR and integrins transcripts proceeded in 50 ml of a reaction mixture containing 1 ml of RT material . To ensure the quality of the procedure, RT-PCR was performed on the same samples using specific primers for b-actin. 9 , or 10 10 VP in a 100-ml phosphate-buffered saline (PBS). Two days later, the brain, lung, heart, spleen, kidney, and liver were removed, weighed, and homogenized in PBS containing 10 mg/ml aprotinin and 100 mM phenylmethylsulfonyl fluoride. (b) C57BL/6 mice were intradermally injected with 2 Â 10 5 B16 BL6 cells, and then tumors with diameters of 5-7 mm were injected with Ad-Luc and AdRGD-Luc at 10 8 , 10 9 , or 10 10 VP in a 50-ml PBS. Two days later, the tumor and liver were removed and treated as described above. Luciferase activity in the homogenates was determined by a luciferase assay system (PicaGene LT2.0, Toyo Inki Co. Ltd, Tokyo, Japan). All data represent the mean7s.e. of 3 (a) or 6 (b) experiments. The mean background value of luciferase activity in each organ has been subtracted from the data. N.D.: luciferase activity was not detectable.
Adverse effects of gene therapy using TNFa-expressing Ad Y Okada et al also maintains a specific blood vessel structure in which a fenestra (up to 100 nm in diameter) is observed. 22 We, therefore, determined that the accumulation of Ad (80-100 nm in particle size) in the liver was intimately related to these characteristics and that morphological changes in the liver can be used as index for evaluating the effects of Ad leakage upon intratumoral injection of Ad at high doses.
We also measured luciferase activity on day 2 in both B16 BL6 tumors and livers in mice injected intratumorally with AdRGD-Luc or Ad-Luc at 10 8 , 10 9 , or 10 10 VP (Figure 2b ). For both Ad types, gene expression in tumors increased in an Ad-dose-dependent manner, and gene expression in the liver, which reflected the amount of Ad leaked from tumor to blood flow, also increased with Ad dosage. However, mice treated with AdRGDLuc exhibited lower ratios of liver to tumor luciferase activity than those treated with Ad-Luc. These results demonstrated that compared with conventional Ad, AdRGD did not leak as freely from the injected tumors due to its highly efficient infection of melanoma cells. The data also supported the utility of AdRGD for melanoma gene therapy as described previously. 4, 5 In addition, luciferase activity in the livers of mice injected intratumorally with AdRGD-Luc or Ad-Luc at 10 10 VP (Figure 2b ) was comparable to that in mice injected intravenously with each vector at 10 8 VP (Figure 2a ). Therefore, we determined that the rate of Ad leakage from the B16 BL6 tumors to systemic circulation was about 1% of the administered VP in the case of intratumoral injection with AdRGD or conventional Ad at 10 10 VP. Next, we examined the hepatotoxicity of Ad itself or the expression product derived from the gene carried by the Ad. No pathological changes were observed on day 3 after treatment in livers from mice injected intravenously with 10 10 VP Ad-Luc or AdRGD-Luc (Figure 3b and c) . Likewise, livers from mice injected intravenously with Ad-Luc, (c) 10 10 AdRGD-Luc, or (d) 10 9 AdRGD-TNFa. Mice with an intradermal B16 BL6 tumor (5-7 mm in diameter) were intratumorally injected with (e) 10 10 Ad-TNFa or (f) 10 10 AdRGD-TNFa. Liver was removed from these mice on day 2 after Ad treatment and from intact mice (a), placed in neutral 10% formalin/PBS, and embedded in paraffin. Sections (5 mm) were prepared for hematoxylin and eosin staining and histopathological examination.
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AdRGD-TNFa at 10 9 VP were normal (Figure 3d ). These results demonstrated that neither Ad itself nor TNFa expression in the liver caused by Ad leakage from the tumors induced the side effects. On the other hand, ballooning degeneration, the presence of acidophilic bodies, and abnormalities of the nucleus suggested remarkable hepatotoxicity in the livers of mice injected intratumorally with Ad-TNFa or AdRGD-TNFa at 10 10 VP (Figure 3e and f) . Moreover, a denaturated appearance was also observed in most digestive organs of these mice (data not shown). Therefore, we speculated that the adverse effects, including hepatotoxicity, observed in mice injected intratumorally with 10 10 VP AdTNFa or AdRGD-TNFa were caused by the leakage of TNFa that was produced in excess by the tumor.
We, therefore, investigated the correlation between TNFa concentration in blood and changes in body weight of mice injected intratumorally with 10 10 VP AdTNFa or AdRGD-TNFa. AdRGD-TNFa-injected mice exhibited higher TNFa concentrations than Ad-TNFainjected mice on day 1 post-Ad treatment. A rapid decrease in TNFa concentration was then observed on day 2 (Figure 4a ). On the other hand, TNFa concentrations in blood from Ad-TNFa-injected mice continued to rise for 2 days after treatment. We previously demonstrated that intratumoral injection of 10 9 VPAdRGD-TNFa could induce severe hemolytic necrosis over a large area in B16 BL6 tumors on day 2, whereas tumors injected with 10 9 VP Ad-TNFa showed only partial necrosis. 5 Therefore, the residual ratio of melanoma cells expressing TNFa for two days post-Ad treatment might account for the differences in the TNFa concentration profiles of blood from Ad-TNFa-and AdRGD-TNFa-injected mice. Early stage B16 BL6 melanomas injected with AdRGDTNFa could produce and secrete high levels of TNFa due to the high transduction efficiency of AdRGD, which resulted in rapid tumor injury and high TNFa leakage. On day 2 after treatment, the number of TNFa-expressing melanoma cells was markedly reduced, and as a result, TNFa concentration in blood rapidly decreased because the stability of TNFa was very poor. [10] [11] [12] On the other hand, because a therapeutic effect of TNFa has been delayed in Ad-TNFa-injected melanomas due to lower transduction efficiency of conventional Ad, surviving Ad-infected melanoma cells continued to express TNFa, and high TNFa concentrations were Adverse effects of gene therapy using TNFa-expressing Ad Y Okada et al maintained in the blood. Responding to differences in TNFa concentration profiles, the body weight of AdRGD-TNFainjected mice began to recover on day 2, whereas the body weight of Ad-TNFa-injected mice continued to decrease over the 2 days (Figure 4b) . Furthermore, when body weight reduction was plotted against TNFa concentration in blood from all examined mice, a very high correlation (R¼0.938) was identified by the least-squares method (Figure 4c ). TNFa in blood was undetectable in mice injected intratumorally or intravenously with 10 9 VP AdTNFa or AdRGD-TNFa, and their body weight change was not influenced at all by Ad treatment (data not shown). These results strongly suggested that the adverse effects observed in mice injected intratumorally with AdTNFa or AdRGD-TNFa at 10 10 VP were caused by TNFa leakage from B16 BL6 tumors, which triggered systemic inflammatory reactions.
Therefore, in order to avoid the side effects of gene therapy using AdRGD-TNFa for treatment of malignant melanomas, the administered dosage must not lead to transient or high TNFa leakage from the tumors into systemic circulation. Morr et al also reported that systemic toxicity and antitumor activity were simultaneously enhanced by intratumoral injection of Adexpressing human TNFa depending on the Ad dosage and the TNFa expression levels in infected tumors. 23 In our experimental model, the optimal AdRGD-TNFa dose that demonstrated effective tumor regression without elevated TNFa concentrations in the blood was 10 9 VP. The determination of a limiting dose may be important for safe clinical application of AdRGD-TNFa gene therapy in the future. If anti-tumor effects are inadequate below the limiting dose, combining the AdRGD-TNFa with AdRGDs expressing other cytokines should be investigated. We previously found that B16 BL6 tumors injected with a mixture of AdRGD-TNFa and interleukin-12-expressing AdRGD showed a more effective regression than tumors injected with either alone. 4 Recently, Kianmanesh et al reported that the combination of TNFa-expressing conventional Ad at a low dose with intratumoral administration of dendritic cells (powerful antigen-presenting cells) was effective for the regression of several murine established tumors without side effects. 24 In addition, the application of Ad expressing a membrane-bound form of TNFa may be one powerful strategy of suppressing side effects by preventing the leakage of soluble TNFa from infected tumors. 25 In conclusion, although genetic modification of malignant melanomas by AdRGD-TNFa is a very attractive strategy for attaining locally elevated concentrations of TNFa while limiting the systemic use of high doses of TNFa, proper dosages of AdRGD-TNFa must be established to prevent systemic side effects caused by high TNFa leakage from tumors into systemic circulation. We believe that this caution can be applied to other therapeutic designs using genes coding for secretory cytokines that display strong side effects.
